Journal article
Loss of type I IFN responsiveness impairs natural killer cell antitumor activity in breast cancer
DJ Zanker, KL Owen, N Baschuk, AJ Spurling, BS Parker
Cancer Immunology Immunotherapy | SPRINGER | Published : 2021
Abstract
Competent type I IFN signaling is the lynchpin of most immune surveillance mechanisms and has recently proven critical to the efficacy of several anticancer agents. Expression of the type I IFN receptor, IFNAR, underpins type I IFN responsiveness in all cells and facilitates the activation and cytotoxic potential of lymphocytes, while loss of IFNAR on lymphocytes has previously been associated with tumor progression and poor patient survival. This study underscores the importance of intact type I IFN signaling to NK cells in the regulation of tumorigenesis and metastasis, whereby ablation of NK cell IFNAR1 impairs antitumor activity and tumor clearance. Using a preclinical model of triple ne..
View full abstractGrants
Awarded by Victorian Cancer Agency
Funding Acknowledgements
We thank the LARTF and Peter MacCallum Cancer Centre animal facility staff for assistance monitoring experimental animals. We thank Dr. Paul Beavis for the gifting of the B16F10 cell line. We thank Prof Christian Engwerda and Dr Fiona Amante at the QIMR Berghofer for the gifting of C57BL/6 Ifnar<SUP>fl/fl</SUP> and NKp46<SUP>iCre</SUP> mice. We acknowledge fellowship support from the Victorian Cancer Agency (BSP) and grant funding from the Cancer Council Victoria (BSP) for this work.